In this OpenBriefing Bluechiip Limited (ASX:BCT) (FRA:1BL) Managing Director Andrew McLellan Discusses Growing customer base, repeat orders, pipeline growth and FujiFilm Irvine Scientific Progress.
Asymmetrex Will Discuss the Impact of Its Technology for Dosing Therapeutic Stem Cells
Share Article
During the coming months of May and June, stem cell biotechnology company Asymmetrex is invited to give presentations in several different virtual conferences that span the fields of clinical trial supply, cell biotherapeutics, stem cell science, and stem cell medicine. The company’s relevance to these diverse disciplines reflects the broad scope of the impact of its emerging technologies for determining the dosage of therapeutic stem cells.
Asymmetrex President & CEO
James L. Sherley, M.D., Ph.D.
It’s basic medicine. Finally knowing the stem cell dosage of stem cell treatments must necessarily be better for patients.